Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAZF1 adenovirus vector (Ad-JAZF1) is a recombinant adenoviral vector designed to overexpress juxtaposed with another zinc finger gene 1 (JAZF1). JAZF1 is a transcriptional co-repressor and nuclear receptor regulator implicated in glucose and lipid metabolism, insulin sensitivity, and chronic inflammation. In preclinical research, Ad-JAZF1 is utilized to investigate the metabolic effects of JAZF1 overexpression in various tissues, such as the hypothalamus, liver, and adipose tissue. Studies have shown that central or peripheral administration of Ad-JAZF1 can suppress hepatic glucose production, enhance insulin signaling, reduce triglyceride accumulation, and modulate inflammatory pathways, making it a valuable tool for studying type 2 diabetes, obesity, and hepatic steatosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JAZF1 adenovirus vector.